MEP35308A - COMPOUNDS SPECIFIC TO ADENOSINE A1, A2a, AND A3 RECEPTOR AND USES THEREOF - Google Patents

COMPOUNDS SPECIFIC TO ADENOSINE A1, A2a, AND A3 RECEPTOR AND USES THEREOF

Info

Publication number
MEP35308A
MEP35308A MEP-353/08A MEP35308A MEP35308A ME P35308 A MEP35308 A ME P35308A ME P35308 A MEP35308 A ME P35308A ME P35308 A MEP35308 A ME P35308A
Authority
ME
Montenegro
Prior art keywords
adenosine
compounds
receptor
compounds specific
subjects
Prior art date
Application number
MEP-353/08A
Other languages
Bosnian (bs)
Inventor
Arlindo L Castelhano
Bryan Mckibben
David J Witter
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/728,607 external-priority patent/US6664252B2/en
Priority claimed from US09/728,616 external-priority patent/US7160890B2/en
Priority claimed from US09/728,316 external-priority patent/US6680322B2/en
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of MEP35308A publication Critical patent/MEP35308A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Predmetni pronalazak se odnosi na jedinjenja koja specifično inhibiraju adenozinske A1, A2a i A3 receptore, kao i na upotrebu ovih jedinjenja u liječenju oboljenja povezanih sa A1, A2a i A3 adenozinskim receptorima u subjektima, koja obuhvata primjenu terapijski efikasnih količina jedinjenja na subjektima.The present invention relates to compounds that specifically inhibit adenosine A1, A2a and A3 receptors, as well as to the use of these compounds in the treatment of diseases associated with A1, A2a and A3 adenosine receptors in subjects, comprising administering therapeutically effective amounts of the compounds to subjects.

MEP-353/08A 2000-12-01 2001-11-30 COMPOUNDS SPECIFIC TO ADENOSINE A1, A2a, AND A3 RECEPTOR AND USES THEREOF MEP35308A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/728,607 US6664252B2 (en) 1999-12-02 2000-12-01 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US09/728,616 US7160890B2 (en) 1999-12-02 2000-12-01 Compounds specific to adenosine A3 receptor and uses thereof
US09/728,316 US6680322B2 (en) 1999-12-02 2000-12-01 Compounds specific to adenosine A1 receptors and uses thereof
PCT/US2001/045280 WO2002057267A1 (en) 2000-12-01 2001-11-30 Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof
YU42703A YU42703A (en) 2000-12-01 2001-11-30 Compounds specific to adenosine a1, a2a and a3 receptor and uses thereof

Publications (1)

Publication Number Publication Date
MEP35308A true MEP35308A (en) 2011-02-10

Family

ID=27419112

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-353/08A MEP35308A (en) 2000-12-01 2001-11-30 COMPOUNDS SPECIFIC TO ADENOSINE A1, A2a, AND A3 RECEPTOR AND USES THEREOF

Country Status (20)

Country Link
EP (1) EP1347980A4 (en)
JP (1) JP4579497B2 (en)
CN (1) CN1263757C (en)
AP (1) AP1893A (en)
AU (1) AU2002248151B2 (en)
BR (1) BR0115847A (en)
CA (1) CA2430577A1 (en)
CZ (1) CZ20031831A3 (en)
EA (1) EA007254B1 (en)
HU (1) HUP0400692A3 (en)
IL (1) IL155962A0 (en)
ME (1) MEP35308A (en)
MX (1) MXPA03004717A (en)
NO (1) NO327207B1 (en)
NZ (1) NZ525885A (en)
OA (1) OA13295A (en)
PL (1) PL363245A1 (en)
WO (1) WO2002057267A1 (en)
YU (1) YU42703A (en)
ZA (1) ZA200303729B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5090531A (en) * 1990-01-10 1992-02-25 Lord Corporation Electrophoretic fluid differential
AR020590A1 (en) 1998-06-02 2002-05-22 Cadus Pharmaceutical Corp 7-DIAZAPURINA-N-6 REPLACED, A METHOD FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND IT
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
DE10148883A1 (en) * 2001-10-04 2003-04-10 Merck Patent Gmbh New fused bi- or tricyclic pyrimidine derivatives, are phosphodiesterase V inhibitors useful e.g. for treating impotence, cardiovascular disorders, inflammation or tumors
AU2002360436A1 (en) 2001-11-30 2003-06-17 Osi Pharmaceuticals, Inc. 2-aryl pyrrologpyrimidines for a1 and a3 receptors
EP2198867A1 (en) * 2001-12-07 2010-06-23 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as GSK-3 inhibitors
DE60236458D1 (en) 2001-12-20 2010-07-01 Osi Pharm Inc PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONISTIC COMPOUNDS, THEIR SYNTHESIS AND USE
US6916804B2 (en) 2001-12-20 2005-07-12 Osi Pharmaceuticals, Inc. Pyrimidine A2b selective antagonist compounds, their synthesis and use
WO2004041285A1 (en) * 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents
HUP0203976A3 (en) * 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (en) 2004-10-25 2006-05-31 Astex Therapeutics Ltd SUBSTITUTED DERIVATIVES OF PURINA, PURINONA AND DEAZAPURINA, COMPOSITIONS THAT CONTAIN METHODS FOR THEIR PREPARATION AND ITS USES
EP2043655A2 (en) 2006-04-25 2009-04-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
TW200808819A (en) * 2006-06-19 2008-02-16 Solvay Pharm Gmbh Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty
PL2201012T3 (en) 2007-10-11 2014-11-28 Astrazeneca Ab Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors
JP2011509290A (en) 2008-01-11 2011-03-24 ナトコ ファーマ リミテッド Pyrazolo [3,4-D] pyrimidine derivatives as anticancer agents
AR070127A1 (en) 2008-01-11 2010-03-17 Novartis Ag PIRROLO - PIRIMIDINAS AND PIRROLO -PIRIDINAS
ES2761311T3 (en) 2011-04-01 2020-05-19 Astrazeneca Ab Therapeutic treatment
MY175800A (en) 2011-11-30 2020-07-09 Astrazeneca Ab Combination treatment of cancer
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
MX2014014832A (en) * 2012-06-07 2015-02-12 Hoffmann La Roche Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase.
SI3010503T1 (en) 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novel bicyclic bromodomain inhibitors
JP6461118B2 (en) 2013-06-21 2019-01-30 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． Novel substituted bicyclic compounds as bromodomain inhibitors
KR20160038008A (en) 2013-07-31 2016-04-06 제니쓰 에피제네틱스 코포레이션 Novel quinazolinones as bromodomain inhibitors
CA2966303A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
CA2966298A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
EP3230277B1 (en) 2014-12-11 2019-09-18 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
EP3233846A4 (en) 2014-12-17 2018-07-18 Zenith Epigenetics Ltd. Inhibitors of bromodomains
HUE064003T2 (en) * 2015-01-20 2024-02-28 Wuxi Fortune Pharmaceutical Co Ltd Jak inhibitor
AU2016254385B2 (en) 2015-04-29 2018-05-10 Wuxi Fortune Pharmaceutical Co., Ltd JAK inhibitors
PT3305788T (en) 2015-05-29 2020-09-25 Wuxi Fortune Pharmaceutical Co Ltd Janus kinase inhibitor
CN105771672B (en) * 2016-04-18 2018-03-02 天津工业大学 A kind of antipollution antibiotic aromatic polyamide reverse osmosis composite film and preparation method
CN108570054B (en) * 2017-03-07 2021-07-16 广州再极医药科技有限公司 Aminopyrimidine five-membered heterocyclic compound, intermediate thereof, preparation method, pharmaceutical composition and application
CN108017584B (en) * 2017-06-20 2021-03-23 南开大学 A3Small molecule antagonists of adenosine receptors
AU2019282098B2 (en) * 2018-06-04 2023-12-14 Evotec International Gmbh Pyrazolopyrimidine compounds as adenosine receptor antagonists
CN110128316B (en) * 2019-05-22 2021-08-31 北京大学深圳研究生院 Preparation method of 5-substituted beta-proline and derivatives thereof
CN110272373B (en) * 2019-07-02 2022-07-29 天津国际生物医药联合研究院 Selective adenosine A 1 Receptor antagonists and uses thereof
CN114085178A (en) * 2021-12-29 2022-02-25 苏州楚凯药业有限公司 Preparation method of 4-methyl-1-propyl-2-amino-1H-pyrrole-3-nitrile

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE177101T1 (en) * 1992-12-17 1999-03-15 Pfizer PYRROLOPYRIMIDINES AS CRF ANTAGONISTS
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
AR020590A1 (en) * 1998-06-02 2002-05-22 Cadus Pharmaceutical Corp 7-DIAZAPURINA-N-6 REPLACED, A METHOD FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND IT
AU784878B2 (en) * 1999-12-02 2006-07-13 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 A2A and A3 receptors and uses thereof
AU2002360436A1 (en) * 2001-11-30 2003-06-17 Osi Pharmaceuticals, Inc. 2-aryl pyrrologpyrimidines for a1 and a3 receptors

Also Published As

Publication number Publication date
HUP0400692A3 (en) 2007-09-28
EA007254B1 (en) 2006-08-25
PL363245A1 (en) 2004-11-15
NZ525885A (en) 2005-01-28
NO20032482L (en) 2003-07-28
HUP0400692A2 (en) 2004-07-28
AP1893A (en) 2008-09-23
NO20032482D0 (en) 2003-06-02
CA2430577A1 (en) 2002-07-25
WO2002057267A1 (en) 2002-07-25
EA200300628A1 (en) 2003-12-25
ZA200303729B (en) 2004-05-14
EP1347980A4 (en) 2005-02-09
JP4579497B2 (en) 2010-11-10
AU2002248151B2 (en) 2008-02-21
OA13295A (en) 2007-04-13
AP2003002807A0 (en) 2003-06-30
CN1489590A (en) 2004-04-14
NO327207B1 (en) 2009-05-11
MXPA03004717A (en) 2004-06-30
JP2004517896A (en) 2004-06-17
EP1347980A1 (en) 2003-10-01
CZ20031831A3 (en) 2004-05-12
YU42703A (en) 2006-03-03
BR0115847A (en) 2004-02-25
IL155962A0 (en) 2003-12-23
CN1263757C (en) 2006-07-12

Similar Documents

Publication Publication Date Title
MEP35308A (en) COMPOUNDS SPECIFIC TO ADENOSINE A1, A2a, AND A3 RECEPTOR AND USES THEREOF
TR200103233T2 (en) New drug compositions on the basis of anticholinergic compounds and ß-mimetics.
BR0108977A (en) Azacyclic compounds for use in the treatment of serotonin-related diseases
WO2002043652A3 (en) Anti-proliferative drugs
DK1450811T3 (en) Compounds specific for adenosine A1 and A3 receptors and uses thereof
MY140010A (en) Purine compounds and use thereof as cannabinoid receptor ligands
MX2007004882A (en) Xanthine derivatives with hm74a receptor activity.
PA8514401A1 (en) NEW DERIVATIVES OF PIPERAZINA
BR0308429A (en) Monocyclic Aroylpyridinones as Anti-Inflammatory Agents
AU4550801A (en) Herbal composition phy906 and its use in chemotheraphy
IL199869A0 (en) Compounds specific to adenosine a1,a2a and a3 receptors and uses thereof
TW200510343A (en) Substituted dihydroquinazolines
BR0111358A (en) Thioacetamide compounds and their use
CO5160321A1 (en) NEW COMPOSITIONS OF TIPRANAVIR AND RITONAVIR
MXPA03009185A (en) Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson s disease.
TR199802769T2 (en) Topical composition containing a combination of terpenoid compounds and antihistamine compounds.
ATE516366T1 (en) REGULATED APTAMER THERAPEUTICS
BRPI0409359A (en) somatostatin-dopamine chimeric analogs
YU60101A (en) Resorcinol derivatives
SE0004101D0 (en) New use
TR200200246T2 (en) Composition related to prevention and treatment of symptoms associated with cold and flu-like diseases.
BR0009194A (en) Composition of resorcinol
MY124071A (en) Treatment of viral disease in swine
SE0000303D0 (en) Novel compounds
MXPA05012772A (en) Benzothiazole derivatives and use thereof in the treatment of diseases related to the adenosine a2a receptor.